NO20022948L - Partially saturated calcium channel blocking compounds - Google Patents
Partially saturated calcium channel blocking compoundsInfo
- Publication number
- NO20022948L NO20022948L NO20022948A NO20022948A NO20022948L NO 20022948 L NO20022948 L NO 20022948L NO 20022948 A NO20022948 A NO 20022948A NO 20022948 A NO20022948 A NO 20022948A NO 20022948 L NO20022948 L NO 20022948L
- Authority
- NO
- Norway
- Prior art keywords
- calcium channel
- partially saturated
- channel blocking
- saturated calcium
- blocking compounds
- Prior art date
Links
- 150000001669 calcium Chemical class 0.000 title 1
- 230000008061 calcium-channel-blocking effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17276599P | 1999-12-20 | 1999-12-20 | |
| US47692999A | 1999-12-30 | 1999-12-30 | |
| PCT/CA2000/001558 WO2001046166A2 (en) | 1999-12-20 | 2000-12-20 | Partially saturated calcium channel blockers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20022948D0 NO20022948D0 (en) | 2002-06-19 |
| NO20022948L true NO20022948L (en) | 2002-08-19 |
| NO326939B1 NO326939B1 (en) | 2009-03-16 |
Family
ID=26868438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20022948A NO326939B1 (en) | 1999-12-20 | 2002-06-19 | Calcium channel blocking compounds and pharmaceutical composition |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1242398A2 (en) |
| JP (1) | JP2003518107A (en) |
| AU (1) | AU784848B2 (en) |
| CA (1) | CA2397681C (en) |
| MX (1) | MXPA02006137A (en) |
| NO (1) | NO326939B1 (en) |
| WO (1) | WO2001046166A2 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2563304T3 (en) | 2003-04-24 | 2016-03-14 | Incyte Holdings Corporation | Azaespiro alkane derivatives as metalloprotease inhibitors |
| ATE313532T1 (en) | 2003-07-22 | 2006-01-15 | Arena Pharm Inc | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONINE RECEPTOR, SUITABLE FOR THE PROPHYLAXIS AND TREATMENT OF RELATED DISEASES |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| MXPA06014486A (en) | 2004-06-15 | 2007-03-01 | Pfizer | Benzimidazolone carboxylic acid derivatives. |
| JP2008511552A (en) | 2004-08-30 | 2008-04-17 | ニューロメッド ファーマシューティカルズ リミテッド | Urea derivatives as calcium channel blockers |
| US7511077B2 (en) | 2005-02-09 | 2009-03-31 | Neuromed Pharmaceuticals Ltd. | Diamine calcium channel blockers |
| EP1856110B1 (en) | 2005-02-22 | 2011-06-22 | Pfizer Inc. | Oxyindole derivatives as 5ht4 receptor agonists |
| WO2008031227A1 (en) * | 2006-09-14 | 2008-03-20 | Neuromed Pharmaceuticals Ltd. | Diaryl piperidine compounds as calcium channel blockers |
| TWI415845B (en) | 2006-10-03 | 2013-11-21 | Arena Pharm Inc | Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| MY148880A (en) | 2006-10-20 | 2013-06-14 | Astrazeneca Ab | N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression |
| WO2009023253A2 (en) | 2007-08-15 | 2009-02-19 | Arena Pharmaceuticals Inc. | IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| HUE036506T2 (en) | 2008-10-28 | 2018-07-30 | Arena Pharm Inc | Compositions comprising a 5-HT2A serotonin receptor modulator for the treatment of disorders associated with such receptor modulators |
| WO2011148888A1 (en) | 2010-05-27 | 2011-12-01 | あすか製薬株式会社 | Heterocyclic ring compound and h1 receptor antagonist |
| EP3288527B1 (en) | 2015-04-28 | 2020-02-19 | Unilever PLC, a company registered in England and Wales under company no. 41424 of | N-aralkylcarbonyldiamine compounds and personal care compositions comprising the same |
| EP3288926B1 (en) | 2015-04-28 | 2021-01-20 | Unilever PLC | N-aralkylcarbonyl-piperazine and -homopiperazine compounds and personal care compositions comprising the same |
| CA2989343A1 (en) | 2015-06-12 | 2016-12-15 | Yandong Wen | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder |
| JP2018520187A (en) | 2015-07-15 | 2018-07-26 | アクソヴァント サイエンシーズ ゲゼルシャフト ミット ベシュレンクテル ハフツングAxovant Sciences GmbH | Diaryl and arylheteroaryl urea derivatives as modulators of 5-HT2A serotonin receptors useful for the prevention and treatment of hallucinations associated with neurodegenerative diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703071A (en) * | 1990-08-29 | 1997-12-30 | Pharmacia & Upjohn Company | Tropolone derivatives and pharmaceutical composition thereof for preventing and treating ischemic diseases |
| DE4111861A1 (en) * | 1991-04-11 | 1992-10-15 | Schwabe Willmar Gmbh & Co | BENZOPYRANONE, PROCESS FOR THEIR PREPARATION AND USE |
| US5292726A (en) * | 1991-05-22 | 1994-03-08 | Merck & Co., Inc. | N,N-diacylpiperazines |
| BR9406080A (en) * | 1993-12-08 | 1996-02-06 | Alcon Lab Inc | Compounds that have both potent anaonist antivity and antioxidant activity and their use as cytoprotective agents |
| KR20010013387A (en) * | 1997-06-16 | 2001-02-26 | 디르크 반테 | Use of draflazine-analogues for treating pain |
| US6251919B1 (en) * | 1998-02-27 | 2001-06-26 | Warner-Lambert | Heterocyclic substituted aniline calcium channel blockers |
| US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
-
2000
- 2000-12-20 AU AU24957/01A patent/AU784848B2/en not_active Ceased
- 2000-12-20 MX MXPA02006137A patent/MXPA02006137A/en unknown
- 2000-12-20 JP JP2001547077A patent/JP2003518107A/en active Pending
- 2000-12-20 EP EP00988532A patent/EP1242398A2/en not_active Withdrawn
- 2000-12-20 CA CA2397681A patent/CA2397681C/en not_active Expired - Fee Related
- 2000-12-20 WO PCT/CA2000/001558 patent/WO2001046166A2/en active Application Filing
-
2002
- 2002-06-19 NO NO20022948A patent/NO326939B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001046166A2 (en) | 2001-06-28 |
| CA2397681C (en) | 2011-03-15 |
| AU2495701A (en) | 2001-07-03 |
| NO20022948D0 (en) | 2002-06-19 |
| AU784848B2 (en) | 2006-07-06 |
| NO326939B1 (en) | 2009-03-16 |
| JP2003518107A (en) | 2003-06-03 |
| CA2397681A1 (en) | 2001-06-28 |
| EP1242398A2 (en) | 2002-09-25 |
| WO2001046166A3 (en) | 2002-03-07 |
| MXPA02006137A (en) | 2002-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20022948D0 (en) | Partially saturated calcium channel blocking compounds | |
| EP1296699A4 (en) | THERAPEUTIC COMPOUNDS | |
| NO20024042L (en) | Aryl-fused azapolycyclic compounds | |
| NO20026196L (en) | Kinazolinditosylatsalt compounds | |
| LTC1124961I2 (en) | THROMBOPOETINE COMPOUNDS | |
| ATE229954T1 (en) | BETACARBOLINE COMPOUNDS | |
| ID28266A (en) | AMIDIN COMPOUNDS | |
| DE69905038D1 (en) | CYCLIC BOROPROLIN COMPOUNDS | |
| EE200100502A (en) | Compounds | |
| NO20011745L (en) | compounds | |
| NO20015722D0 (en) | Antibacterial compounds | |
| ID27004A (en) | CALSILITIC COMPOUNDS | |
| ATE362919T1 (en) | LACTAM COMPOUNDS | |
| ATE405580T1 (en) | ANTITHRBOTIC COMPOUNDS | |
| ATE258921T1 (en) | ARYL-ANNELLED AZAPOLYCYCLIC COMPOUNDS | |
| NO20006662L (en) | Fluorfenylresin compounds | |
| NO20013769L (en) | Calcilitic compounds | |
| ATE372338T1 (en) | DESHALOGEN COMPOUNDS | |
| NO20020466L (en) | Calcilitic compounds | |
| NO20030303L (en) | Calcilitic compounds | |
| NO20031837D0 (en) | Calcilitic compounds | |
| NO20023508L (en) | Calcilitic compounds | |
| DK1175417T3 (en) | Substituted benzolactam compounds | |
| ATE235487T1 (en) | S-OXYDE LIPIDE-LOWERING COMPOUNDS | |
| DE50108778D1 (en) | Dialkyne compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |